#Japan #Kawasaki #Accelerator #Helioverse

Accelerating Innovation: Helioverse Innovations Inc. Chosen for Kawasaki Deep Tech Accelerator

Helioverse Innovations Inc., a pioneer in medical technology based in Ohio, has secured acceptance into the prestigious Kawasaki Deep Tech Accelerator program for the year 2025. This initiative, organized by Kawasaki City and supported by upto4 Inc., focuses on aiding research-oriented startups. Helioverse is on a mission to develop a compact, cable-free artificial heart, addressing significant issues in the current artificial heart treatments.

A New Era in Cardiac Care

The significance of artificial hearts in medical treatment cannot be overstated. Previously deemed nearly impossible, patients suffering from end-stage heart failure are now finding hope, with survival rates exceeding 70% over five years. However, existing devices often require large power cables that must penetrate the skin, posing serious risks of infection that may affect as many as 22% of patients, impacting their Quality of Life (QOL). Helioverse aims to revolutionize this technology with a tiny, wireless, fully implantable artificial heart that spares patients from the dangers associated with traditional devices.

Collaborative Innovation: Merging Research and Technology

Helioverse Innovations has teamed up with the renowned Cleveland Clinic, known for having one of the world's longest histories in artificial heart research, and an elite group of engineers from Japan specializing in high-precision manufacturing. Together, they are focused on creating a fully implantable wireless power source that will allow for the safe delivery of high currents to the artificial heart. The goal is to initiate clinical trials by 2030, paving the way for this groundbreaking product to enter the market.

Support from Kawasaki City

Kawasaki City is home to various research and development hubs, including the Kanagawa Science Park and Kings Skyfront, renowned for its collaboration between academia and industry. The Kawasaki Deep Tech Accelerator program is designed to support researchers and early-stage entrepreneurs by utilizing intellectual property from universities and companies. Through this program, Helioverse has begun discussions with two partner companies to expedite their development efforts.

Statements from Leadership

CEO Taiyo Kuroda expressed that the team encompasses an array of talents, including medical professionals from the Cleveland Clinic, power electronics engineers, business leaders, and legal experts specializing in regulations. The shared ambition is to accelerate the development of a safe device that restores patients' normal lives, focusing on the need for innovative solutions in healthcare.

CMO Makoto Kawazoe highlighted the current state of Japan's medical device market, where imports accounted for over 66.5% of a total market worth approximately 2.8 trillion yen in 2021. He emphasized the strengths of Japanese companies in component manufacturing and precision engineering, positioning the revival of manufacturing and robust healthcare technologies as vital for Japan's global competitiveness.

The Future of Healthcare Technology

Moving forward, Helioverse Innovations Inc. is committed to maximizing the support from the Kawasaki Deep Tech Accelerator, preparing for preclinical trials by developing the first generation of a supplemental artificial heart prototype by March 2026. The company sees this initiative as a critical milestone toward achieving a cable-free artificial heart, combining Japan’s manufacturing prowess with U.S. clinical research expertise.

As Kawasaki City fosters a robust ecosystem for manufacturing in the medical and robotic fields, Helioverse stands at the forefront of innovation, dedicated to delivering revolutionary medical devices that could change countless lives worldwide.

For more information on Helioverse Innovations, visit their website or reach out via email at [email protected].